New CAR t therapy targets hidden leukemia cells in early remission
NCT ID NCT05535855
First seen Nov 15, 2025 · Last updated May 13, 2026 · Updated 26 times
Summary
This early-phase trial tests whether a new type of CAR T cell therapy (UCD19) is safe and can work in adults with B-cell acute lymphoblastic leukemia (B-ALL) who are in first remission but still have tiny amounts of cancer cells (minimal residual disease). About 29 participants will receive the treatment after chemotherapy. The study will monitor side effects and check if the therapy can clear remaining cancer cells and prevent relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.